The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Recombinant Human Insulin Market Research Report 2025
Synopsis
Insulin is a well-characterized peptide that can be produced byrecombinant DNA technology for human therapeutic use.
The global Recombinant Human Insulin market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Recombinant Human Insulin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Recombinant Human Insulin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Recombinant Human Insulin include Akron Biotech, Wockhardt, Dance Biopharm, Novo Nordisk, Gan & Lee, United Laboratories and Dongbro Pharmaceuticri, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Recombinant Human Insulin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Human Insulin.
Report Scope
The Recombinant Human Insulin market size, estimations, and forecasts are provided in terms of sales volume (g) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Human Insulin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Human Insulin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Akron Biotech
Wockhardt
Dance Biopharm
Novo Nordisk
Gan & Lee
United Laboratories
Dongbro Pharmaceuticri
Segment by Type
by Recombinant DNA Technology Using Fermentation in Bacteria Way
by Recombinant DNA Technology Using Fermentation in Yeast Way
Segment by Application
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Human Insulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Human Insulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Insulin is a well-characterized peptide that can be produced byrecombinant DNA technology for human therapeutic use.
The global Recombinant Human Insulin market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Recombinant Human Insulin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Recombinant Human Insulin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Recombinant Human Insulin include Akron Biotech, Wockhardt, Dance Biopharm, Novo Nordisk, Gan & Lee, United Laboratories and Dongbro Pharmaceuticri, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Recombinant Human Insulin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Human Insulin.
Report Scope
The Recombinant Human Insulin market size, estimations, and forecasts are provided in terms of sales volume (g) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Human Insulin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Human Insulin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Akron Biotech
Wockhardt
Dance Biopharm
Novo Nordisk
Gan & Lee
United Laboratories
Dongbro Pharmaceuticri
Segment by Type
by Recombinant DNA Technology Using Fermentation in Bacteria Way
by Recombinant DNA Technology Using Fermentation in Yeast Way
Segment by Application
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Human Insulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Human Insulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Recombinant Human Insulin Market Overview
1.1 Product Overview and Scope of Recombinant Human Insulin
1.2 Recombinant Human Insulin Segment by Recombinant DNA Technology Using Fermentation in Bacteria Way
1.2.1 Global Recombinant Human Insulin Market Value Comparison by Recombinant DNA Technology Using Fermentation in Bacteria Way (2024-2030)
1.2.2 by Recombinant DNA Technology Using Fermentation in Bacteria Way
1.2.3 by Recombinant DNA Technology Using Fermentation in Yeast Way
1.3 Recombinant Human Insulin Segment by Application
1.3.1 Global Recombinant Human Insulin Market Value by Application: (2024-2030)
1.3.2 Type 1 Diabetes Mellitus
1.3.3 Type 2 Diabetes Mellitus
1.4 Global Recombinant Human Insulin Market Size Estimates and Forecasts
1.4.1 Global Recombinant Human Insulin Revenue 2019-2030
1.4.2 Global Recombinant Human Insulin Sales 2019-2030
1.4.3 Global Recombinant Human Insulin Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Recombinant Human Insulin Market Competition by Manufacturers
2.1 Global Recombinant Human Insulin Sales Market Share by Manufacturers (2019-2024)
2.2 Global Recombinant Human Insulin Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Recombinant Human Insulin Average Price by Manufacturers (2019-2024)
2.4 Global Recombinant Human Insulin Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Recombinant Human Insulin, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant Human Insulin, Product Type & Application
2.7 Recombinant Human Insulin Market Competitive Situation and Trends
2.7.1 Recombinant Human Insulin Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Recombinant Human Insulin Players Market Share by Revenue
2.7.3 Global Recombinant Human Insulin Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Recombinant Human Insulin Retrospective Market Scenario by Region
3.1 Global Recombinant Human Insulin Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Recombinant Human Insulin Global Recombinant Human Insulin Sales by Region: 2019-2030
3.2.1 Global Recombinant Human Insulin Sales by Region: 2019-2024
3.2.2 Global Recombinant Human Insulin Sales by Region: 2025-2030
3.3 Global Recombinant Human Insulin Global Recombinant Human Insulin Revenue by Region: 2019-2030
3.3.1 Global Recombinant Human Insulin Revenue by Region: 2019-2024
3.3.2 Global Recombinant Human Insulin Revenue by Region: 2025-2030
3.4 North America Recombinant Human Insulin Market Facts & Figures by Country
3.4.1 North America Recombinant Human Insulin Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Recombinant Human Insulin Sales by Country (2019-2030)
3.4.3 North America Recombinant Human Insulin Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Recombinant Human Insulin Market Facts & Figures by Country
3.5.1 Europe Recombinant Human Insulin Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Recombinant Human Insulin Sales by Country (2019-2030)
3.5.3 Europe Recombinant Human Insulin Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant Human Insulin Market Facts & Figures by Country
3.6.1 Asia Pacific Recombinant Human Insulin Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Recombinant Human Insulin Sales by Country (2019-2030)
3.6.3 Asia Pacific Recombinant Human Insulin Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Recombinant Human Insulin Market Facts & Figures by Country
3.7.1 Latin America Recombinant Human Insulin Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Recombinant Human Insulin Sales by Country (2019-2030)
3.7.3 Latin America Recombinant Human Insulin Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Recombinant Human Insulin Market Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant Human Insulin Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Recombinant Human Insulin Sales by Country (2019-2030)
3.8.3 Middle East and Africa Recombinant Human Insulin Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Recombinant Human Insulin Sales by Type (2019-2030)
4.1.1 Global Recombinant Human Insulin Sales by Type (2019-2024)
4.1.2 Global Recombinant Human Insulin Sales by Type (2025-2030)
4.1.3 Global Recombinant Human Insulin Sales Market Share by Type (2019-2030)
4.2 Global Recombinant Human Insulin Revenue by Type (2019-2030)
4.2.1 Global Recombinant Human Insulin Revenue by Type (2019-2024)
4.2.2 Global Recombinant Human Insulin Revenue by Type (2025-2030)
4.2.3 Global Recombinant Human Insulin Revenue Market Share by Type (2019-2030)
4.3 Global Recombinant Human Insulin Price by Type (2019-2030)
5 Segment by Application
5.1 Global Recombinant Human Insulin Sales by Application (2019-2030)
5.1.1 Global Recombinant Human Insulin Sales by Application (2019-2024)
5.1.2 Global Recombinant Human Insulin Sales by Application (2025-2030)
5.1.3 Global Recombinant Human Insulin Sales Market Share by Application (2019-2030)
5.2 Global Recombinant Human Insulin Revenue by Application (2019-2030)
5.2.1 Global Recombinant Human Insulin Revenue by Application (2019-2024)
5.2.2 Global Recombinant Human Insulin Revenue by Application (2025-2030)
5.2.3 Global Recombinant Human Insulin Revenue Market Share by Application (2019-2030)
5.3 Global Recombinant Human Insulin Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Akron Biotech
6.1.1 Akron Biotech Corporation Information
6.1.2 Akron Biotech Description and Business Overview
6.1.3 Akron Biotech Recombinant Human Insulin Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Akron Biotech Recombinant Human Insulin Product Portfolio
6.1.5 Akron Biotech Recent Developments/Updates
6.2 Wockhardt
6.2.1 Wockhardt Corporation Information
6.2.2 Wockhardt Description and Business Overview
6.2.3 Wockhardt Recombinant Human Insulin Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Wockhardt Recombinant Human Insulin Product Portfolio
6.2.5 Wockhardt Recent Developments/Updates
6.3 Dance Biopharm
6.3.1 Dance Biopharm Corporation Information
6.3.2 Dance Biopharm Description and Business Overview
6.3.3 Dance Biopharm Recombinant Human Insulin Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Dance Biopharm Recombinant Human Insulin Product Portfolio
6.3.5 Dance Biopharm Recent Developments/Updates
6.4 Novo Nordisk
6.4.1 Novo Nordisk Corporation Information
6.4.2 Novo Nordisk Description and Business Overview
6.4.3 Novo Nordisk Recombinant Human Insulin Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Novo Nordisk Recombinant Human Insulin Product Portfolio
6.4.5 Novo Nordisk Recent Developments/Updates
6.5 Gan & Lee
6.5.1 Gan & Lee Corporation Information
6.5.2 Gan & Lee Description and Business Overview
6.5.3 Gan & Lee Recombinant Human Insulin Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Gan & Lee Recombinant Human Insulin Product Portfolio
6.5.5 Gan & Lee Recent Developments/Updates
6.6 United Laboratories
6.6.1 United Laboratories Corporation Information
6.6.2 United Laboratories Description and Business Overview
6.6.3 United Laboratories Recombinant Human Insulin Sales, Revenue and Gross Margin (2019-2024)
6.6.4 United Laboratories Recombinant Human Insulin Product Portfolio
6.6.5 United Laboratories Recent Developments/Updates
6.7 Dongbro Pharmaceuticri
6.6.1 Dongbro Pharmaceuticri Corporation Information
6.6.2 Dongbro Pharmaceuticri Description and Business Overview
6.6.3 Dongbro Pharmaceuticri Recombinant Human Insulin Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Dongbro Pharmaceuticri Recombinant Human Insulin Product Portfolio
6.7.5 Dongbro Pharmaceuticri Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Recombinant Human Insulin Industry Chain Analysis
7.2 Recombinant Human Insulin Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant Human Insulin Production Mode & Process
7.4 Recombinant Human Insulin Sales and Marketing
7.4.1 Recombinant Human Insulin Sales Channels
7.4.2 Recombinant Human Insulin Distributors
7.5 Recombinant Human Insulin Customers
8 Recombinant Human Insulin Market Dynamics
8.1 Recombinant Human Insulin Industry Trends
8.2 Recombinant Human Insulin Market Drivers
8.3 Recombinant Human Insulin Market Challenges
8.4 Recombinant Human Insulin Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Recombinant Human Insulin Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Recombinant Human Insulin Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Recombinant Human Insulin Market Competitive Situation by Manufacturers in 2023
Table 4. Global Recombinant Human Insulin Sales (g) of Key Manufacturers (2019-2024)
Table 5. Global Recombinant Human Insulin Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Recombinant Human Insulin Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Recombinant Human Insulin Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Recombinant Human Insulin Average Price (USD/mg) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Recombinant Human Insulin, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Recombinant Human Insulin, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Recombinant Human Insulin, Product Type & Application
Table 12. Global Key Manufacturers of Recombinant Human Insulin, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Recombinant Human Insulin by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Human Insulin as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Recombinant Human Insulin Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Recombinant Human Insulin Sales by Region (2019-2024) & (g)
Table 18. Global Recombinant Human Insulin Sales Market Share by Region (2019-2024)
Table 19. Global Recombinant Human Insulin Sales by Region (2025-2030) & (g)
Table 20. Global Recombinant Human Insulin Sales Market Share by Region (2025-2030)
Table 21. Global Recombinant Human Insulin Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Recombinant Human Insulin Revenue Market Share by Region (2019-2024)
Table 23. Global Recombinant Human Insulin Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Recombinant Human Insulin Revenue Market Share by Region (2025-2030)
Table 25. North America Recombinant Human Insulin Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Recombinant Human Insulin Sales by Country (2019-2024) & (g)
Table 27. North America Recombinant Human Insulin Sales by Country (2025-2030) & (g)
Table 28. North America Recombinant Human Insulin Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Recombinant Human Insulin Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Recombinant Human Insulin Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Recombinant Human Insulin Sales by Country (2019-2024) & (g)
Table 32. Europe Recombinant Human Insulin Sales by Country (2025-2030) & (g)
Table 33. Europe Recombinant Human Insulin Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Recombinant Human Insulin Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Recombinant Human Insulin Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Recombinant Human Insulin Sales by Region (2019-2024) & (g)
Table 37. Asia Pacific Recombinant Human Insulin Sales by Region (2025-2030) & (g)
Table 38. Asia Pacific Recombinant Human Insulin Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Recombinant Human Insulin Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Recombinant Human Insulin Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Recombinant Human Insulin Sales by Country (2019-2024) & (g)
Table 42. Latin America Recombinant Human Insulin Sales by Country (2025-2030) & (g)
Table 43. Latin America Recombinant Human Insulin Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Recombinant Human Insulin Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Recombinant Human Insulin Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Recombinant Human Insulin Sales by Country (2019-2024) & (g)
Table 47. Middle East & Africa Recombinant Human Insulin Sales by Country (2025-2030) & (g)
Table 48. Middle East & Africa Recombinant Human Insulin Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Recombinant Human Insulin Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Recombinant Human Insulin Sales (g) by Type (2019-2024)
Table 51. Global Recombinant Human Insulin Sales (g) by Type (2025-2030)
Table 52. Global Recombinant Human Insulin Sales Market Share by Type (2019-2024)
Table 53. Global Recombinant Human Insulin Sales Market Share by Type (2025-2030)
Table 54. Global Recombinant Human Insulin Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Recombinant Human Insulin Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Recombinant Human Insulin Revenue Market Share by Type (2019-2024)
Table 57. Global Recombinant Human Insulin Revenue Market Share by Type (2025-2030)
Table 58. Global Recombinant Human Insulin Price (USD/mg) by Type (2019-2024)
Table 59. Global Recombinant Human Insulin Price (USD/mg) by Type (2025-2030)
Table 60. Global Recombinant Human Insulin Sales (g) by Application (2019-2024)
Table 61. Global Recombinant Human Insulin Sales (g) by Application (2025-2030)
Table 62. Global Recombinant Human Insulin Sales Market Share by Application (2019-2024)
Table 63. Global Recombinant Human Insulin Sales Market Share by Application (2025-2030)
Table 64. Global Recombinant Human Insulin Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Recombinant Human Insulin Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Recombinant Human Insulin Revenue Market Share by Application (2019-2024)
Table 67. Global Recombinant Human Insulin Revenue Market Share by Application (2025-2030)
Table 68. Global Recombinant Human Insulin Price (USD/mg) by Application (2019-2024)
Table 69. Global Recombinant Human Insulin Price (USD/mg) by Application (2025-2030)
Table 70. Akron Biotech Corporation Information
Table 71. Akron Biotech Description and Business Overview
Table 72. Akron Biotech Recombinant Human Insulin Sales (g), Revenue (US$ Million), Price (USD/mg) and Gross Margin (2019-2024)
Table 73. Akron Biotech Recombinant Human Insulin Product
Table 74. Akron Biotech Recent Developments/Updates
Table 75. Wockhardt Corporation Information
Table 76. Wockhardt Description and Business Overview
Table 77. Wockhardt Recombinant Human Insulin Sales (g), Revenue (US$ Million), Price (USD/mg) and Gross Margin (2019-2024)
Table 78. Wockhardt Recombinant Human Insulin Product
Table 79. Wockhardt Recent Developments/Updates
Table 80. Dance Biopharm Corporation Information
Table 81. Dance Biopharm Description and Business Overview
Table 82. Dance Biopharm Recombinant Human Insulin Sales (g), Revenue (US$ Million), Price (USD/mg) and Gross Margin (2019-2024)
Table 83. Dance Biopharm Recombinant Human Insulin Product
Table 84. Dance Biopharm Recent Developments/Updates
Table 85. Novo Nordisk Corporation Information
Table 86. Novo Nordisk Description and Business Overview
Table 87. Novo Nordisk Recombinant Human Insulin Sales (g), Revenue (US$ Million), Price (USD/mg) and Gross Margin (2019-2024)
Table 88. Novo Nordisk Recombinant Human Insulin Product
Table 89. Novo Nordisk Recent Developments/Updates
Table 90. Gan & Lee Corporation Information
Table 91. Gan & Lee Description and Business Overview
Table 92. Gan & Lee Recombinant Human Insulin Sales (g), Revenue (US$ Million), Price (USD/mg) and Gross Margin (2019-2024)
Table 93. Gan & Lee Recombinant Human Insulin Product
Table 94. Gan & Lee Recent Developments/Updates
Table 95. United Laboratories Corporation Information
Table 96. United Laboratories Description and Business Overview
Table 97. United Laboratories Recombinant Human Insulin Sales (g), Revenue (US$ Million), Price (USD/mg) and Gross Margin (2019-2024)
Table 98. United Laboratories Recombinant Human Insulin Product
Table 99. United Laboratories Recent Developments/Updates
Table 100. Dongbro Pharmaceuticri Corporation Information
Table 101. Dongbro Pharmaceuticri Description and Business Overview
Table 102. Dongbro Pharmaceuticri Recombinant Human Insulin Sales (g), Revenue (US$ Million), Price (USD/mg) and Gross Margin (2019-2024)
Table 103. Dongbro Pharmaceuticri Recombinant Human Insulin Product
Table 104. Dongbro Pharmaceuticri Recent Developments/Updates
Table 105. Key Raw Materials Lists
Table 106. Raw Materials Key Suppliers Lists
Table 107. Recombinant Human Insulin Distributors List
Table 108. Recombinant Human Insulin Customers List
Table 109. Recombinant Human Insulin Market Trends
Table 110. Recombinant Human Insulin Market Drivers
Table 111. Recombinant Human Insulin Market Challenges
Table 112. Recombinant Human Insulin Market Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Recombinant Human Insulin
Figure 2. Global Recombinant Human Insulin Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Recombinant Human Insulin Market Share by Type in 2023 & 2030
Figure 4. Product Picture
Figure 5. Product Picture
Figure 6. Global Recombinant Human Insulin Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Recombinant Human Insulin Market Share by Application in 2023 & 2030
Figure 8. Type 1 Diabetes Mellitus
Figure 9. Type 2 Diabetes Mellitus
Figure 10. Global Recombinant Human Insulin Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 11. Global Recombinant Human Insulin Market Size (2019-2030) & (US$ Million)
Figure 12. Global Recombinant Human Insulin Sales (2019-2030) & (g)
Figure 13. Global Recombinant Human Insulin Average Price (USD/mg) & (2019-2030)
Figure 14. Recombinant Human Insulin Report Years Considered
Figure 15. Recombinant Human Insulin Sales Share by Manufacturers in 2023
Figure 16. Global Recombinant Human Insulin Revenue Share by Manufacturers in 2023
Figure 17. The Global 5 and 10 Largest Recombinant Human Insulin Players: Market Share by Revenue in 2023
Figure 18. Recombinant Human Insulin Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 19. Global Recombinant Human Insulin Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 20. North America Recombinant Human Insulin Sales Market Share by Country (2019-2030)
Figure 21. North America Recombinant Human Insulin Revenue Market Share by Country (2019-2030)
Figure 22. U.S. Recombinant Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 23. Canada Recombinant Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Europe Recombinant Human Insulin Sales Market Share by Country (2019-2030)
Figure 25. Europe Recombinant Human Insulin Revenue Market Share by Country (2019-2030)
Figure 26. Germany Recombinant Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. France Recombinant Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. U.K. Recombinant Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Italy Recombinant Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Russia Recombinant Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Asia Pacific Recombinant Human Insulin Sales Market Share by Region (2019-2030)
Figure 32. Asia Pacific Recombinant Human Insulin Revenue Market Share by Region (2019-2030)
Figure 33. China Recombinant Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Japan Recombinant Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. South Korea Recombinant Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. India Recombinant Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Australia Recombinant Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Taiwan Recombinant Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Indonesia Recombinant Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Thailand Recombinant Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Malaysia Recombinant Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Philippines Recombinant Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Latin America Recombinant Human Insulin Sales Market Share by Country (2019-2030)
Figure 44. Latin America Recombinant Human Insulin Revenue Market Share by Country (2019-2030)
Figure 45. Mexico Recombinant Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Brazil Recombinant Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Argentina Recombinant Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa Recombinant Human Insulin Sales Market Share by Country (2019-2030)
Figure 49. Middle East & Africa Recombinant Human Insulin Revenue Market Share by Country (2019-2030)
Figure 50. Turkey Recombinant Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Saudi Arabia Recombinant Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. U.A.E Recombinant Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Global Sales Market Share of Recombinant Human Insulin by Type (2019-2030)
Figure 54. Global Revenue Market Share of Recombinant Human Insulin by Type (2019-2030)
Figure 55. Global Recombinant Human Insulin Price (USD/mg) by Type (2019-2030)
Figure 56. Global Sales Market Share of Recombinant Human Insulin by Application (2019-2030)
Figure 57. Global Revenue Market Share of Recombinant Human Insulin by Application (2019-2030)
Figure 58. Global Recombinant Human Insulin Price (USD/mg) by Application (2019-2030)
Figure 59. Recombinant Human Insulin Value Chain
Figure 60. Recombinant Human Insulin Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
